Illness intrusiveness and subjective well-being in patients with glioblastoma

Journal of Neuro-Oncology

Volumn 126, Issue 1, 2016, Pages 127-135

  Edelstein, Kim ^a,b   Coate, Linda ^c   Massey, Christine ^a   Jewitt, Natalie C ^a   Mason, Warren P ^a,b   Devins, Gerald M ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HOSPITAL LIMERICK   (Ireland)

Author keywords

Brain tumor; Disease burden; GBM; High grade glioma; Mood; Psychosocial; Quality of life

Indexed keywords

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE ASSOCIATION; FEMALE; GLIOBLASTOMA; HUMAN; ILLNESS INTRUSIVENESS; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE; SELF REPORT; SOCIAL DETERMINANTS OF HEALTH; WELLBEING; BRAIN TUMOR; COMPLICATION; COST OF ILLNESS; MIDDLE AGED; MOOD DISORDERS; NONPARAMETRIC TEST; PSYCHOLOGY; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADULT; AGED; BRAIN NEOPLASMS; COST OF ILLNESS; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; QUALITY OF LIFE; REGRESSION ANALYSIS; SELF REPORT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 84951568127     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1943-6     Document Type: Article

References (45)

1. CBTRUS. CBTRUS Statistic Report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2006. Hinsdale, IL: Central Brain Tumor Registry of the United States, 2010
2. Liu R, Page M, Solheim K, Fox S, Chang SM (2009) Quality of life in adults with brain tumors: current knowledge and future directions. Neuro Oncol 11(3):330–339
3. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466
4. Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K (2008) Temozolomide for high grade glioma. Cochrane Database Syst Rev 4:Cd007415
5. Hart MG, Garside R, Rogers G, Stein K, Grant R (2013) Temozolomide for high grade glioma. Cochrane Database Syst Rev 4:Cd007415
6. Taphoorn MJ, Stupp R, Coens C et al (2005) Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol 6(12):937–944
7. Henriksson R, Asklund T, Poulsen HS (2011) Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol 104(3):639–646
8. Armstrong TS, Mendoza T, Gning I et al (2006) Validation of the M.D. Anderson symptom inventory brain tumor module (MDASI-BT). J Neurooncol 80(1):27–35
9. Armstrong TS, Vera-Bolanos E, Gning I et al (2011) The impact of symptom interference using the MD Anderson symptom inventory-brain tumor module (MDASI-BT) on prediction of recurrence in primary brain tumor patients. Cancer 117(14):3222–3228
10. Armstrong TS, Vera-Bolanos E, Acquaye AA, Gilbert MR, Ladha H, Mendoza T (2015) The symptom burden of primary brain tumors: evidence for a core set of tumor and treatment-related symptoms. Neuro Oncol. doi:10.1093/neuonc/nov166
11. Lee JH, Jung TY, Jung S et al (2013) Performance status during and after radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme. J Clin Neurosci 20(4):503–508
12. Chaichana KL, Halthore AN, Parker SL et al (2011) Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. Clinical article. J Neurosurg 114(3):604–612
13. Jones LW, Cohen RR, Mabe SK et al (2009) Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing. J Neurooncol 94(1):79–85
14. Recht L, Glantz M, Chamberlain M, Hsieh CC (2003) Quantitative measurement of quality outcome in malignant glioma patients using an independent living score (ILS). Assessment of a retrospective cohort. J Neurooncol 61(2):127–136
15. Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376
16. Osoba D, Aaronson NK, Muller M et al (1996) The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 5(1):139–150
17. Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA (1995) The functional assessment of cancer therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75(5):1151–1161
18. Chow R, Lao N, Popovic M et al (2014) Comparison of the EORTC QLQ-BN20 and the FACT-Br quality of life questionnaires for patients with primary brain cancers: a literature review. Support Care Cancer 22(9):2593–2598
19. Wefel JS, Cloughesy T, Zazzali JL et al (2011) Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol 13(6):660–668
20. Meyers CA, Hess KR (2003) Multifaceted end points in brain tumor clinical trials: cognitive deterioration precedes MRI progression. Neuro Oncol 5(2):89–95
21. Meyers CA, Hess KR, Yung WK, Levin VA (2000) Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol 18(3):646–650
22. Bradburn N (1969) The structure of psychological well-being. Aldine, Chicago
23. Devins GM (2010) Using the illness intrusiveness ratings scale to understand health-related quality of life in chronic disease. J Psychosom Res 68(6):591–602
24. Devins GM, Bezjak A, Mah K, Loblaw DA, Gotowiec AP (2006) Context moderates illness-induced lifestyle disruptions across life domains: a test of the illness intrusiveness theoretical framework in six common cancers. Psychooncology 15(3):221–233
25. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655
26. Krull KR, Gioia G, Ness KK et al (2008) Reliability and validity of the Childhood cancer survivor study neurocognitive questionnaire. Cancer 113(8):2188–2197
27. Radloff L (1977) The CES–D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1:385–401
28. Costello C, Devins G (1988) Screening for stressful life events and chronic difficulties. Can JBehav Sci 20:85–92
29. Cohen J, Cohen P, West S, Aiken L (2003) Applied multiple regression/correlation analysis for the behavioral sciences, 3rd edn. Lawrence Erlbaum Associates, Mahwah
30. Kanter C, Daniels M, Stone A, Edelstein K, D’Agostino N (2010) A demographic and thematic overview of the brain tumour patient and caregiver support groups at Princess Margaret Hospital. Psycho-Oncology 19(Suppl. 2):S231
31. Devins GM, Edworthy SM, Seland TP, Klein GM, Paul LC, Mandin H (1993) Differences in illness intrusiveness across rheumatoid arthritis, end-stage renal disease, and multiple sclerosis. J Nerv Ment Dis 181(6):377–381
32. Devins GM, Edworthy SM, Paul LC et al (1993) Restless sleep, illness intrusiveness, and depressive symptoms in three chronic illness conditions: rheumatoid arthritis, end-stage renal disease, and multiple sclerosis. J Psychosom Res 37(2):163–170
33. Snyder S, Foley FW, Farrell E, Beier M, Zemon V (2013) Psychological and physical predictors of illness intrusiveness in patients with multiple sclerosis. J Neurol Sci 332(1–2):41–44
34. Shawaryn MA, Schiaffino KM, LaRocca NG, Johnston MV (2002) Determinants of health-related quality of life in multiple sderosis: the role of illness intrusiveness. Mult Scler 8(4):310–318
35. Turpin KV, Carroll LJ, Cassidy JD, Hader WJ (2007) Deterioration in the health-related quality of life of persons with multiple sclerosis: the possible warning signs. Mult Scler 13(8):1038–1045
36. Poochikian-Sarkissian S, Sidani S, Wennberg RA, Devins GM (2008) Psychological impact of illness intrusiveness in epilepsy—comparison of treatments. Psychol Health Med 13(2):129–145
37. Klein M, Reijneveld JC, Heimans JJ (2008) Subjective ratings versus objective measurement of cognitive function: in regard to Van Beek et al. (Int J Radiat Oncol Biol Phys 2007; 68:986–991). Int J Radiat Oncol Biol Phys. United States, 70: 961–962; author reply 962
38. Gehring K, Sitskoorn MM, Gundy CM et al (2009) Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. J Clin Oncol 27(22):3712–3722
39. Edelstein K, Bernstein LJ (2014) Cognitive dysfunction after chemotherapy for breast cancer. J Int Neuropsychol Soc 20(4):351–356
40. Hermelink K, Kuchenhoff H, Untch M et al (2010) Two different sides of ‘chemobrain’: determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology 19(12):1321–1328
41. Kelvin JF, Steed R, Jarrett J (2014) Discussing safe sexual practices during cancer treatment. Clin J Oncol Nurs 18(4):449–453
42. Surbeck W, Herbet G, Duffau H (2015) Sexuality after surgery for diffuse low-grade glioma. Neuro Oncol 17(4):574–579
43. Krychman ML, Amsterdam A, Carter J, Castiel M, DeAngelis L (2004) Brain cancer and sexual health: a case report. Palliat Support Care 2(3):315–318
44. Khan F, Amatya B, Ng L, Drummond K, Olver J (2013) Multidisciplinary rehabilitation after primary brain tumour treatment. Cochrane Database Syst Rev 1:Cd009509
45. Addeo R, Perri F, Parlato C, Della Vittoria G (2014) ASCO 2013: bevacizumab and glioblastoma—a marriage dissolution? Curr Med Res Opin 30:1871–1873